10-Q: Interpace Biosciences Q2 Loss Amid PancraGEN Medicare Cut

Interpace Biosciences reported a net loss of $0.64 million in Q2 2025, primarily due to the loss of Medicare reimbursement for its PancraGEN test and associated restructuring costs.

Summary

• Net revenue for the three months ended June 30, 2025, decreased by 23% to $9.2 million from $12.0 million in the comparable prior year period.
• The company reported a net loss of $0.64 million for Q2 2025, a significant decline from a net income of $2.44 million in Q2 2024.
• For the six months ended June 30, 2025, net income was $1.01 million, down from $3.15 million in the prior year period.
• The loss of Medicare coverage for the PancraGEN molecular test, effective April 24, 2025, led to the company ceasing to offer the test and accept specimens after May 2, 2025.
• A restructuring plan was implemented, resulting in $0.5 million in severance costs in Q2 2025 and $0.7 million for the six months ended June 30, 2025.
• An asset impairment charge of $0.2 million related to PancraGEN lab supplies was recorded in Q2 2025.
• Cash and cash equivalents decreased to $0.5 million as of June 30, 2025, from $1.46 million at December 31, 2024.
• The Term Loan maturity date with BroadOak was extended to December 31, 2025, with $1.9 million outstanding.
• A material weakness in internal control over financial reporting related to royalty expense accrual was identified as of December 31, 2024, rendering disclosure controls ineffective as of June 30, 2025.

Sentiment

Score: 3

Explanation: The company experienced a substantial decline in revenue and swung to a net loss in Q2 2025 due to the loss of Medicare reimbursement for its key PancraGEN test. This necessitated a restructuring and led to asset impairment. While operating cash flow was positive and the debt maturity was extended, significant risks remain regarding future profitability, capital raising capabilities, and internal control effectiveness. The impending delisting from OTCQX further compounds market access challenges.

Positives

• Net cash provided by operating activities increased to $1.76 million for the six months ended June 30, 2025, compared to $1.35 million in the prior year period.
• Total stockholders deficit improved to $(1.21) million as of June 30, 2025, from $(2.22) million at December 31, 2024.
• The company anticipates current cash and forecasted cash receipts will be sufficient to meet anticipated cash requirements through the next twelve months, despite the loss of PancraGEN.
• The Term Loan maturity date was extended to December 31, 2025, providing additional liquidity runway.

Negatives

• Net revenue decreased by 23% in Q2 2025 and 7% for the six months ended June 30, 2025, primarily due to the loss of PancraGEN Medicare reimbursement.
• The company swung to a net loss of $0.64 million in Q2 2025 from a net income of $2.44 million in Q2 2024.
• Operating income from continuing operations significantly decreased to a loss of $0.47 million in Q2 2025 from an income of $2.63 million in Q2 2024.
• Gross profit margin declined to 57.1% in Q2 2025 from 64.8% in Q2 2024.
• Cash and cash equivalents declined from $1.46 million at December 31, 2024, to $0.50 million at June 30, 2025, and approximately $1.0 million as of August 1, 2025.
• Incurred $0.7 million in restructuring and severance costs for the six months ended June 30, 2025.
• Recorded a $0.2 million asset impairment charge related to PancraGEN lab supplies.
• Disclosure controls and procedures were deemed ineffective due to a material weakness in internal control over financial reporting.
• The company's Common Stock is facing impending removal from trading on the OTCQX on August 18, 2025, for failure to meet market capitalization requirements.

Risks

• Reliance on Medicare reimbursement for clinical services and the ability to successfully restructure and maintain profitability after the loss of PancraGEN coverage.
• The secured lender has the right to foreclose on substantially all assets if outstanding obligations are not timely repaid.
• Dependence on sales and reimbursements from clinical services for all revenue.
• Ability to finance the business on acceptable terms in the future, which may limit growth, product development, and commercialization.
• Dependence on third parties for the supply of materials used in clinical services tests.
• Potential adverse impact of current and future laws, licensing requirements, and governmental regulations, including the evolving U.S. regulatory environment for laboratory developed tests (LDTs), pricing, and patient access limitations.
• Reliance on sales and marketing activities for future business growth and the ability to continue to expand these activities.
• Controlling interests of two private equity investors (Ampersand and 1315 Capital) who control 84.0% of outstanding Common Stock (as-converted basis) as of August 1, 2025, which may substantially influence decisions.
• Adverse effects on Common Stock and business from the delisting from Nasdaq in February 2021.
• The effect of the impending removal of Common Stock on August 18, 2025, from trading on the OTCQX for failure to meet market capitalization requirements.
• Ability to remediate the material weakness identified in internal control over financial reporting as of June 30, 2025.
• Potential impact of existing and future contingent liabilities on financial condition.

Future Outlook

The company anticipates that current cash and cash equivalents and forecasted cash receipts will be sufficient to meet its anticipated cash requirements through the next twelve months from the date of the filing, even with the loss of reimbursement coverage of PancraGEN. It continues to explore various strategic alternatives, including dilutive and non-dilutive sources of funding such as equity and debt financings, strategic alliances, and business development, to provide additional liquidity.

Management Comments

• "We intend to meet our ongoing capital needs by using our available cash, as well as through targeted margin improvement; collection of accounts receivable; containment of costs; and the potential use of other financing options and other strategic alternatives."
• "The Company continues to explore various strategic alternatives, dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances, business development and other sources in order to provide additional liquidity."
• "Even with the loss of reimbursement coverage of PancraGEN, as of the date of this filing, the Company anticipates that current cash and cash equivalents and forecasted cash receipts will be sufficient to meet its anticipated cash requirements through the next twelve months from the date of the filing of this report."

Industry Context

The loss of Medicare coverage for PancraGEN due to Local Coverage Determination (LCD) L39365 highlights the significant regulatory risks faced by molecular diagnostics companies, particularly those reliant on government reimbursement for specialized tests. This event reflects a broader trend of increased scrutiny and evolving reimbursement policies for laboratory developed tests (LDTs) in the U.S. oncology space, impacting revenue streams and necessitating rapid operational adjustments and cost-saving measures across the industry.

Corporate Governance

Related Party Transactions

• The Term Loan and Convertible Note agreements are with BroadOak Fund V, L.P., a significant investor.
• The Series C Preferred Stock exchange was with 1315 Capital and Ampersand, who collectively control 84.0% of the company's outstanding common stock (as-converted basis).

Stakeholder Impact

• Shareholders: Significant negative impact due to revenue decline, net loss, and potential future dilution from capital raises or Series C conversion. Impending delisting from OTCQX further reduces liquidity and visibility.
• Employees: Workforce reduction due to the restructuring plan following the loss of PancraGEN, resulting in severance benefits for impacted employees.
• Customers: Loss of PancraGEN test availability after May 2, 2025, impacting patients and physicians who relied on this specific molecular diagnostic.
• Creditors (BroadOak): Debt maturity extended to December 31, 2025, with interest-only payments for several months, indicating ongoing financial management efforts to meet obligations.
• Regulatory Bodies: The company is subject to evolving U.S. regulatory environment related to laboratory developed tests (LDTs) and reimbursement policies, as evidenced by the PancraGEN decision.

Next Steps

• Remediate the material weakness in internal control over financial reporting by holding quarterly meetings between the accounting department and lab management to discuss agreements.
• Continue to explore various strategic alternatives and sources of funding (equity, debt, strategic alliances, business development) to provide additional liquidity.
• Make monthly interest-only payments on the Term Loan from July 1, 2025, through December 1, 2025, with the remaining balance due on December 31, 2025.

Key Dates

Recommendation

The company faces severe headwinds, including a substantial decline in revenue and a swing to net loss due to the loss of Medicare reimbursement for its PancraGEN test. This regulatory setback necessitated a significant restructuring and asset impairment. While management has extended debt maturity and claims sufficient liquidity for 12 months, the company's ability to raise capital is severely hampered by its delisted status and impending removal from OTCQX. The identified material weakness in internal controls adds another layer of operational risk. The concentration of ownership by private equity investors, coupled with the potential for significant dilution from Series C preferred stock conversion, further complicates the investment thesis. Given the deteriorating financial performance, significant operational challenges, and limited access to capital markets, a 'sell' recommendation is warranted for investors seeking to mitigate risk.

Keywords

molecular diagnostics, cancer risk, genomic tests, PancraGEN, Medicare reimbursement, restructuring, financial results, SEC filing, 10-Q, Interpace Biosciences, clinical services, ThyGeNEXT, ThyraMIRv2, RespriDx, liquidity, debt financing, corporate governance, internal controls